Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics

References

• Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997; 389(6653)856–860
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. DSM IV. American Psychiatric Association, Washington, DC 2000
   Google Scholar
• Angelucci F, Mathe AA, Aloe L. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. J Neurosci Res 2000; 60: 783–794
   PubMed Web of Science ®Google Scholar
• Angelucci F, Mathé AA, Aloe L. Neurotrophic factors and CNS disorders: findings in rodent models of depression and schizophrenia. Prog Brain Res 2004; 146: 151–165
   PubMed Web of Science ®Google Scholar
• Angelucci F, Aloe L, Iannitelli A, Gruber SH, Mathe AA. Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain. Eur Neuropharmacology 2005; 15: 311–317
   PubMed Web of Science ®Google Scholar
• Bai O, Chlan-Fourney J, Bowen R, Keegan D, Li XM. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 2003; 71: 127–131
   PubMed Web of Science ®Google Scholar
• Buckley P, Mahadick S, Pillai A, Terry A. Neurotrophins and schizophrenia. Schizophr Res 2007; 94: 1–11
   PubMed Web of Science ®Google Scholar
• Durany N, Michel T, Zochling R, Boissi KW, Cruz-Sánchez FF, Riederer P, et al. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res 2001; 52: 79–86
   PubMed Web of Science ®Google Scholar
• Egan MF, Weinberger DR. Neurobiology of schizophrenia. Curr Opin Neurobiol 1997; 7: 701–707
   PubMed Web of Science ®Google Scholar
• First MB, Spitzer RL, Gibbon M, William JBM. Structured Clinical Interview for DSM-IV Axis I Disorders Patient Edition. Biometrics Research, New York 1997
   Google Scholar
• Guillain O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 2001; 411: 86–89
   PubMedGoogle Scholar
• Grillo RW, Ottoni G, Leke R, Souza DO, Portela LV, Lara DR. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatr Res 2007; 41: 31–35
   PubMed Web of Science ®Google Scholar
• Hall H, Lawyer G, Sillén A, Jönsson EG, Agartz I, Terenius L, et al. Potential genetic variants in schizophrenia: a Bayesian analysis. World J Biol Psychiatry 2007; 8: 12–22
   PubMed Web of Science ®Google Scholar
• Hori H, Yoshimura R, Yamada Y, Ikenouchi A, Mitoma M, Ida Y, et al. Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int Clin Psychopharmacol 2007; 22: 21–27
   PubMed Web of Science ®Google Scholar
• Karege F, Schwald M, Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002; 328: 261–264
   PubMed Web of Science ®Google Scholar
• Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rational and standardization. Br J Psychiatry 1987; 155(Suppl. 7)59–65
   Google Scholar
• Kim T-S, Kim D-J, Lee H, Kim Y-K. Increased plasma brain-derived neurotrophic factor levels in chronic smokers following unaided smoking cessation. Neurosci Lett 2007; 423: 53–57
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Tollefson GD, Charles C, Zipurski R, Sharma T, Kahn RS, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005; 62: 361–370
   PubMed Web of Science ®Google Scholar
• Lieberman JA. Neurobiology and the natural history of schizophrenia. J Clin Psychiatry 2006; 67: e14
   PubMedGoogle Scholar
• Maisonpierre PC, Le Beau MM, Espinosa R, 3rd, Ip NY, Belluscio L, de la Monte SM, et al. Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations. Genomics 1991; 10: 558–568
   PubMed Web of Science ®Google Scholar
• Mathalon DH, Sullivan EV, Lim KO, Pfefferbaum A. Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch Gen Psychiatry 2001; 58: 148–157
   PubMed Web of Science ®Google Scholar
• Pan W, Banks WA, Fasold MB, Bluth J, Kastin A. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998; 37: 1553–1561
   PubMed Web of Science ®Google Scholar
• Pantelis C, Velakoulis D, McGorry PD, Wood SJ, Sucking J, Philips LJ, et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 2003; 361: 281–288
   PubMed Web of Science ®Google Scholar
• Parikh V, Evans D, Khan M, Mahadick S. Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. Schizophr Res 2003; 60: 117–123
   PubMed Web of Science ®Google Scholar
• Parikh V, Khan MM, Mahadick SP. Olanzapine counteracts reduction of brain-derived neurotrophic factor and TrkB receptors in rat hippocampus produced by haloperidol. Neurosci Lett 2004; 356: 135–139
   PubMed Web of Science ®Google Scholar
• Pillai A, Terry AV, Jr, Mahadick SP. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr Res 2006; 82: 95–106
   PubMed Web of Science ®Google Scholar
• Pirildar S, Gonul AS, Taneli F, Akdeniz F. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 709–713
   PubMed Web of Science ®Google Scholar
• Rizos, E, Rontos, I, Laskos, E, Arsenis, G, Michalopoulou, P-G, Vasilopoulos, D, , et al. 2008. Investigation of serum BDNF levels in drug-naïve patients with schizophrenia. Progr Neuro-Psychopharmacol Biol Psychiatry, April 2008
   PubMedGoogle Scholar
• Shoval G, Weizman A. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur Neuropsychopharmacol 2005; 15: 19–329
   Google Scholar
• Suwa M, Kishimoto H, Nofuji Y, Nakano H, Sasaki H, Radak Z, et al. Serum brain-derived neurotrophic factor level is increased and associated with obesity in newly diagnosed female patients with type 2 diabetes mellitus. Metab Clin Exp 2006; 55: 852–857
   PubMed Web of Science ®Google Scholar
• Takahashi M, Shirakawa O, Toyooka K, Kitamura N, Hashimoto T, Maeda Koizumi S, et al. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 2000; 5: 293–300
   PubMed Web of Science ®Google Scholar
• Tan YL, Zhou DF, Cao LY, Zhang XY. Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci Lett 2005; 382: 27–32
   PubMed Web of Science ®Google Scholar
• Thoenen H. Neurotrophins and neuronal plasticity. Science 1995; 270: 593–598
   PubMed Web of Science ®Google Scholar
• Toyooka K, Asama K, Watanabe Y, Muratake T, Takahashi M, Someya T, et al. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 2002; 110: 249–257
   PubMed Web of Science ®Google Scholar
• Velakoulis D, Wood SJ, Wong MT, McGorry PD, Yung A, Philips L, et al. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first–episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry 2006; 63: 139–149
   PubMed Web of Science ®Google Scholar
• Vidal CN, Rapoport JL, Hayashi KM, Geaga JA, Sui Y, McLemore LE, et al. Dynamically spreading frontal and cingulated deficits mapped in adolescents with schizophrenia. Arch Gen Psychiatry 2006; 63: 25–34
   PubMed Web of Science ®Google Scholar
• Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991; 17: 325–351
   PubMed Web of Science ®Google Scholar
• Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2003; 8: 592–610
   PubMed Web of Science ®Google Scholar
• Weickert CS, Ligons DL, Romanczyk T, Ungaro G, Hyde TM, Herman MM, et al. Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2005; 10: 637–650
   PubMed Web of Science ®Google Scholar
• Yoshimura R, Hori H, Sugita A, Ueda N, Kakihara S, Umene W, et al. Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Progr Neuro-Psychopharmacol Biol Psychiatry 2007; 31: 1072–1077
   PubMed Web of Science ®Google Scholar